NASDAQ:ACRX

AcelRx Pharmaceuticals Stock Forecast, Price & News

$1.20

0.00 (0.00 %)

(As of 07/29/2021 12:00 AM ET)

Add

Compare

Today's Range

$1.18

▼

$1.23

50-Day Range

$1.19

▼

$1.67

52-Week Range

$1.02

▼

$2.94

Volume794,372 shs

Average Volume3.88 million shs

Market Capitalization$142.92 million

P/E RatioN/A

Dividend YieldN/A

Beta0.93

30 days | 90 days | 365 days | Advanced Chart

Receive ACRX News and Ratings via Email

Sign-up to receive the latest news and ratings for AcelRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. It also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.

ACRX FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages AcelRx Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 9 Deadline in Securities Class Action – ACRX
July 29, 2021 | feeds.benzinga.com

ACRX & RLX Class Action Reminders: Bronstein, Gewirtz & Grossman LLC
July 27, 2021 | ca.finance.yahoo.com

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages AcelRx Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ACRX
July 27, 2021 | finance.yahoo.com

ACRX LOSS ALERT: ROSEN, A Trusted Investor Law Firm, Encourages AcelRx Pharmaceuticals, Inc. Investors with LARGE LOSSES to Secure Counsel Before Important Deadline in Securities Class Action - ACRX
July 25, 2021 | finance.yahoo.com

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages...
July 21, 2021 | benzinga.com

FINAL DEADLINE NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
July 21, 2021 | finance.yahoo.com

ACRX Investor Notice: Rosen, Trusted Investor Counsel, Encourages AcelRx Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - ACRX
July 20, 2021 | finance.yahoo.com

SHAREHOLDER DEADLINE NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
July 20, 2021 | finance.yahoo.com

DEADLINE ALERT for FREQ, ACRX, RLX, HMPT: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
July 19, 2021 | finance.yahoo.com

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages AcelRx Pharmaceuticals, Inc. Investors With Losses Over $100K to Secure Counsel Before Important August 9 Deadline in Securities Class Action – ACRX
July 19, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ACRX
Previous Symbol
CUSIPN/A
CIK1427925
Webwww.acelrx.com
Phone650-216-3500
Employees54
Year FoundedN/A

Sales & Book Value

Annual Sales$5.42 million
Price / Sales26.37
Cash FlowN/A
Price / Cash FlowN/A
Book Value($0.56) per share
Price / Book-2.14

Profitability

EPS (Most Recent Fiscal Year)($0.47)
Net Income$-40,380,000.00
Net Margins-602.96%
Return on EquityN/A
Return on Assets-46.53%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares119,103,000
Market Cap$142.92 million
Next Earnings Date8/9/2021 (Estimated)
OptionableOptionable

MarketRank^™

Overall MarketRank^™

1.09 out of 5 stars

Medical Sector

1241st out of 2,214 stocks

Pharmaceutical Preparations Industry

583rd out of 869 stocks

0.5 Analyst's Opinion

Consensus Rating
AcelRx Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no buy ratings, no hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $0.84, AcelRx Pharmaceuticals has a forecasted downside of 30.0% from its current price of $1.20.
Amount of Analyst Coverage
AcelRx Pharmaceuticals has received no research coverage in the past 90 days.

3.5 Community Rank

Outperform Votes
AcelRx Pharmaceuticals has received 451 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
AcelRx Pharmaceuticals has received 195 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
AcelRx Pharmaceuticals has received 69.81% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about AcelRx Pharmaceuticals and other stocks. Vote “Outperform” if you believe ACRX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ACRX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
AcelRx Pharmaceuticals does not currently pay a dividend.
Dividend Growth
AcelRx Pharmaceuticals does not have a long track record of dividend growth.

0.8 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, AcelRx Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.20% of the stock of AcelRx Pharmaceuticals is held by insiders.
Percentage Held by Institutions
30.00% of the stock of AcelRx Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for AcelRx Pharmaceuticals are expected to grow in the coming year, from ($0.29) to $0.05 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of AcelRx Pharmaceuticals is -3.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of AcelRx Pharmaceuticals is -3.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

AcelRx Pharmaceuticals (NASDAQ:ACRX) Frequently Asked Questions

Is AcelRx Pharmaceuticals a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AcelRx Pharmaceuticals in the last twelve months. There are currently 1 sell rating for the stock. The consensus among Wall Street analysts is that investors should "sell" AcelRx Pharmaceuticals stock.
View analyst ratings for AcelRx Pharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than AcelRx Pharmaceuticals?

Wall Street analysts have given AcelRx Pharmaceuticals a "Sell" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but AcelRx Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals saw a decline in short interest in June. As of June 30th, there was short interest totaling 10,830,000 shares, a decline of 31.2% from the June 15th total of 15,740,000 shares. Based on an average daily volume of 1,850,000 shares, the short-interest ratio is currently 5.9 days. Currently, 9.3% of the company's shares are short sold.
View AcelRx Pharmaceuticals' Short Interest.

When is AcelRx Pharmaceuticals' next earnings date?

AcelRx Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for AcelRx Pharmaceuticals.

How were AcelRx Pharmaceuticals' earnings last quarter?

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) issued its quarterly earnings data on Sunday, May, 16th. The specialty pharmaceutical company reported ($0.08) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.08). The specialty pharmaceutical company had revenue of $0.51 million for the quarter, compared to analyst estimates of $0.53 million.
View AcelRx Pharmaceuticals' earnings history.

How has AcelRx Pharmaceuticals' stock been impacted by COVID-19?

AcelRx Pharmaceuticals' stock was trading at $1.22 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ACRX stock has decreased by 1.6% and is now trading at $1.20.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for ACRX?

1 equities research analysts have issued 12-month target prices for AcelRx Pharmaceuticals' stock. Their forecasts range from $0.84 to $0.84. On average, they anticipate AcelRx Pharmaceuticals' stock price to reach $0.84 in the next year. This suggests that the stock has a possible downside of 30.0%.
View analysts' price targets for AcelRx Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are AcelRx Pharmaceuticals' key executives?

AcelRx Pharmaceuticals' management team includes the following people:

Mr. Vincent J. Angotti, CEO & Director (Age 53, Pay $932.47k)
Dr. Pamela Pierce Palmer, Co-Founder, Chief Medical Officer & Director (Age 58, Pay $675.76k)
Mr. Raffi Mark Asadorian, Chief Financial Officer (Age 52, Pay $604.36k)
Mr. Anil N. Dasu, Chief Engineering Officer (Age 58, Pay $478.09k)
Mr. Lawrence G. Hamel, Consultant (Age 69)

Who are some of AcelRx Pharmaceuticals' key competitors?

Some companies that are related to AcelRx Pharmaceuticals include Verastem (VSTM), DiaMedica Therapeutics (DMCAF), Albireo Pharma (ALBO), Veru (VERU), Marinus Pharmaceuticals (MRNS), Nabriva Therapeutics (NBRV), Imago BioSciences (IMGO), Evelo Biosciences (EVLO), Pharvaris (PHVS), Spectrum Pharmaceuticals (SPPI), Aldeyra Therapeutics (ALDX), Lexicon Pharmaceuticals (LXRX), AC Immune (ACIU), VistaGen Therapeutics (VTGN) and Greenwich LifeSciences (GLSI).
View all of ACRX's competitors.

What other stocks do shareholders of AcelRx Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AcelRx Pharmaceuticals investors own include Advanced Micro Devices (AMD), Novavax (NVAX), Amarin (AMRN), Amicus Therapeutics (fold), Inovio Pharmaceuticals (INO), TG Therapeutics (TGTX), OPKO Health (OPK), CyberArk Software (CYBR), Flexion Therapeutics (FLXN) and NVIDIA (NVDA).

What is AcelRx Pharmaceuticals' stock symbol?

AcelRx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACRX."

Who are AcelRx Pharmaceuticals' major shareholders?

AcelRx Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Kovack Advisors Inc. (0.03%). Company insiders that own AcelRx Pharmaceuticals stock include Adrian Adams, Mark G Edwards and Vincent J Angotti.
View institutional ownership trends for AcelRx Pharmaceuticals.

Which major investors are buying AcelRx Pharmaceuticals stock?

ACRX stock was bought by a variety of institutional investors in the last quarter, including Kovack Advisors Inc.. Company insiders that have bought AcelRx Pharmaceuticals stock in the last two years include Adrian Adams, Mark G Edwards, and Vincent J Angotti.
View insider buying and selling activity for AcelRx Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of AcelRx Pharmaceuticals?

Shares of ACRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AcelRx Pharmaceuticals' stock price today?

One share of ACRX stock can currently be purchased for approximately $1.20.

How much money does AcelRx Pharmaceuticals make?

AcelRx Pharmaceuticals has a market capitalization of $142.92 million and generates $5.42 million in revenue each year. The specialty pharmaceutical company earns $-40,380,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis.

How many employees does AcelRx Pharmaceuticals have?

AcelRx Pharmaceuticals employs 54 workers across the globe.

What is AcelRx Pharmaceuticals' official website?

The official website for AcelRx Pharmaceuticals is www.acelrx.com.

Where are AcelRx Pharmaceuticals' headquarters?

AcelRx Pharmaceuticals is headquartered at 351 GALVESTON DRIVE, REDWOOD CITY CA, 94063.

How can I contact AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals' mailing address is 351 GALVESTON DRIVE, REDWOOD CITY CA, 94063. The specialty pharmaceutical company can be reached via phone at 650-216-3500 or via email at [email protected]

This page was last updated on 7/30/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here